The drug is approved for multiple inflammatory conditions and is expected to launch in the first half of 2025.

The Food and Drug Administration (FDA) has approved Imuldosa ™ (ustekinumab-srlf), a biosimilar to Stelara ® (ustekinumab), for the treatment of various chronic inflammatory diseases. Imuldosa, ...

Imuldosa is used for the treatment of patients with autoimmune diseases such as plaque psoriasis, psoriatic arthritis, ...

Stelara is one of the most successful Crohn’s therapies, generating $10.8bn last year, Lilly hopes to introduce Omvoh as its ...

Imuldose will be marketed in the United States by Accord BioPharma and is expected to launch in the first half of 2025.

US pharma major Eli Lilly has released new data demonstrating more patients with moderately to severely active Crohn's ...

Lilly announces positive results from phase 3 study of mirikizumab compared to ustekinumab for Crohn's disease: Indianapolis Tuesday, October 15, 2024, 18:00 Hrs [IST] Eli Lilly a ...

Shares of drug maker Eli Lilly ($LLY) were little changed at the time of writing despite announcing results from its Phase 3 ...

Data show more patients treated with mirikizumab achieved histologic response at Week 52 compared to ustekinumab New data are first-of-its-kind analysis of microscopic mucosal resolution that go beyon ...

PRNewswire Ahmedabad Gujarat [India] October 14 Accord BioPharma Inc the US specialty division of Intas Pharmaceuticals Ltd ...

(RTTNews) - Eli Lilly and Company (LLY) Monday announced 1-year histologic data from the Phase 3 VIVID-1 study of mirikizumab in people with Crohn's disease, a type of inflammatory bowel disease.

Accord BioPharma receives US FDA approval for Imuldosa, a biosimilar to Stelara to treat chronic inflammatory conditions: Our Bureau, Mumbai Monday, October 14, 2024, 16:45 Hrs [I ...